drugset / Trial / NCT04756037
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.
Timeline
- Start
- 2021-03-18
- Primary completion
- 2025-02-25
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Estradiol | Other / unclassified | 1 mg | Oral |
| Subject | Norethindrone | Unknown | 0.5 mg | Oral |
| Subject | Relugolix | Small molecule | 40 mg | Oral |
Indications
No indication recorded.